Comparison of short-term adverse reactions of small molecule inhibitors and biologics in the treatment of palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network Meta-analysis. (PubMed, Int Immunopharmacol) - Sep 12, 2026 - "Stratified analyses showed that in PP, adalimumab 40 mg had a lower risk of any AEs (SUCRA: 73.93%) and infections (SUCRA: 79.16%), whereas risankizumab 150 mg had a lower risk of serious AEs (SUCRA: 91.10%). In PPP, guselkumab 100 mg had a lower risk of any AEs (SUCRA: 85.46%) and infections (SUCRA: 81.62%), whereas brodalumab 210 mg had a lower risk of serious AEs (SUCRA: 68.40%). Based on currently available short-term RCT evidence, guselkumab 100 mg had a lower risk of any AEs whereas adalimumab 40 mg ranked more favorably for serious AEs and infections. Given short follow-up durations, few relevant events, and wide credible intervals, all comparative findings should be interpreted with caution."
Journal • Retrospective data • Review • Dermatology • Immunology • Infectious Disease • Inflammation • Psoriasis
|
|
Chanxiu Li; Chenxin Li; Kaige Huang; Linxian Li; Peihan Zhang; Pingping Yang; Shengyi Lei; Yanran Yang; Yijin Zhao; Zhanxue Sun
|